Covidien says it plans to divest its vascular therapies business to mollify U.S. anti-trust regulators about its proposed $43 billion merger with Medtronic.
A look at the top 10 politicial action committee donations shows that medtech is betting heavily on a GOP win in the midterm elections.
The medical device industry is betting on a Republican sweep of the U.S. Congress during the 2014 mid term elections, according to a MassDevice.com analysis of donations made by the industry's 10 largest political action committees.
Medtronic issues an update on the debt financing behind its pending $43 billion acquisition of Covidien.
In this DeviceTalks preview, we catch up with Masimo CEO Joe Kiani to discuss new challenges facing the company and how medtech can break the cycle of the era of 'good-enough' innovation.
Despite stroke being the 2nd leading cause of death worldwide, many people still don't recognize risk factors and warning signs, according to a new poll sponsored by Covidien and the World Stroke Organization.
Shares of Medtronic and Covidien gain after Medtronic affirms its $43 billion acquisition plans, saying it now expects to close the deal for Covidien late this year or early in 2015.
Here's a look at some of the top regulatory stories for medical device companies this week: JNJ continues to pay hefty integration charges on Synthes deal; Stryker: Mako sales not as strong as we hoped; ConvaTec owners appoint banks to explore sale: sources; BD buys Irish next-gen sequencing startup GenCell Biosystems; Valeant says may raise Allergan bid; beats on profit
, Becton Dickinson & Co.
, DePuy Synthes
, GenCell Biosystems
, Johnson & Johnson
, Kimberly-Clark Worldwide Inc.
, MAKO Surgical Corp.
, Stryker Corp.
, Valeant Pharmaceuticals
, 3M Corp.
, Allergan Inc.